| Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate TA Stamey, N Yang, AR Hay, JE McNeal, FS Freiha, E Redwine New England Journal of Medicine 317 (15), 909-916, 1987 | 3461 | 1987 |
| Inflammatory bowel disease: costs-of-illness JW Hay, AR Hay Journal of clinical gastroenterology 14 (4), 309-317, 1992 | 281 | 1992 |
| Inflammatory bowel disease: medical cost algorithms AR Hay, JW Hay Journal of clinical gastroenterology 14 (4), 318-327, 1992 | 121 | 1992 |
| Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement N Shore, R Tutrone, M Efros, M Bidair, B Wachs, S Kalota, S Freedman, ... World journal of urology 36, 801-809, 2018 | 19 | 2018 |
| Am Evaluation of Prostate-Specific Antigen in the Diagnosis and Treatment of Prostate Cancer TA Stamey, AR Hay, JE McNeal, FS Freiha The Journal of Urology 137 (6), 195A-195A, 1987 | 5 | 1987 |
| Hay JW H AR Inflammatory bowel disease: medical cost algorithms. J. Clin. Gastroenterol …, 1992 | 4 | 1992 |
| Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate TA Stamey, N Yang, AR Hay, JE McNeal, FS Freiha, E Redwine The Journal of Urology 139 (5), 1134-1134, 1988 | 3 | 1988 |
| Prostate-specific antigen in adenocarcinoma of the prostate DA Gillatt, MA Ferro, JC Gingell, I Barnes, H Hughes, MD Penney, P Ryan, ... New England Journal of Medicine 318 (15), 992-993, 1988 | 3 | 1988 |
| Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results N Shore, SA Kaplan, R Tutrone, R Levin, J Bailen, A Hay, S Kalota, ... World journal of urology 38, 3101-3111, 2020 | 2 | 2020 |
| Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis Y Wei, JW Hay, AR Hay, S Suen BMC urology 22 (1), 76, 2022 | 1 | 2022 |
| PUK13 FEXAPOTIDE TRIFLUTATE VERSUS PHARMACOTHERAPY AS INITIAL THERAPY FOR PATIENTS WITH MODERATE-TO-SEVERE BENIGN PROSTATE HYPERPLASIA: A COST-EFFECTIVENESS ANALYSIS Y Wei, J Hay, A Hay, SC Suen Value in Health 23, S379, 2020 | | 2020 |
| PROSTATE-SPECIFIC ANTIGEN IN ADENOCARCINOMA OF THE PROSTATE-REPLY TA STAMEY, N YANG, AR HAY, JE MCNEAL, FS FREIHA, E REDWINE NEW ENGLAND JOURNAL OF MEDICINE 318 (15), 993-993, 1988 | | 1988 |
| The Role of Transrectal Ultrasound (TRUS) in the Diagnosis and Management of Prostate Cancer TA Stamey, A Hay, CE Constantinou, J McNeal, FS Freiha The Journal of Urology 137 (6), 242A-242A, 1987 | | 1987 |
Joel HayEx-Professor of Health Economics, University of Southern CaliforniaVerified email at usc.edu
